3
| Company | Price & Valuation | FV & Narrative | Valuation | Growth | Analyst Target | |
|---|---|---|---|---|---|---|
MSFT Microsoft US$499.86n/aintrinsic discount 10.8%7D 20.4%3M The author hasn't set a fair value for MSFT | ||||||
BMY Bristol-Myers Squibb US$64.15n/aintrinsic discount -1.1%7D 14.2%3M The author hasn't set a fair value for BMY | ||||||
CNQ Canadian Natural Resources CA$63.83n/aintrinsic discount -3.6%7D 4.8%3M The author hasn't set a fair value for CNQ |
3
| Company | Price & Valuation | FV & Narrative | Valuation | Growth | Analyst Target | |
|---|---|---|---|---|---|---|
MSFT Microsoft 10.8%7D 20.4%3M | US$499.86 n/aintrinsic discount | The author hasn't set a fair value for MSFT | PE 27.8x | E 14.0% | US$563.35 | |
BMY Bristol-Myers Squibb -1.1%7D 14.2%3M | US$64.15 n/aintrinsic discount | The author hasn't set a fair value for BMY | PE 14.1x | E -6.9% | US$66.21 | |
CNQ Canadian Natural Resources -3.6%7D 4.8%3M | CA$63.83 n/aintrinsic discount | The author hasn't set a fair value for CNQ | PE 13.7x | E -4.7% | CA$70.29 |